Marco Albanese

Marco has been leading Oxford Drug Design’s bacterial histidine kinases inhibitors discovery program with a focus on tackling veterinary pathogens. He employs structure- and ligand-based computational methods to optimise ligand interactions, anti-bacterial activity and pharmacokinetic properties.

Marco earned his Master’s degree in pharmaceutical chemistry and technology from the University of Salerno. In collaboration with the University of Eastern Finland, he completed his thesis applying computational methods on anti-inflammatory and anti-cancer projects. Marco joined Oxford Drug Design in 2018 as part of a Marie Skłodowska-Curie Horizon 2020 Innovation Programme. He is currently completing his PhD at the University of Buckingham.